The phase III study, NINJA (JapicCTI-153004), compared nivolumab (PD-1 inhibitor) with chemotherapy (gemcitabine or pegylated liposomal doxorubicin) in patients with platinum-resistant ovarian cancer. Here, PDCD1 is linked to ovarian carcinoma.